CCX168 specifically targets the C5a receptor, a pro-inflammatory mediator that is involved in AAV as well as other autoimmune diseases.
The randomized, double-blind, placebo-controlled trial will assess the safety and tolerability of CCX168 in patients with ANCA-associated renal vasculitis besides determining the potential to reduce the use of corticosteroids in these patients.
ChemoCentryx president and CEO Thomas J Schall said the company has demonstrated the capabilities of drug discovery platform in blocking specific chemokines and chemoattractant cytokines in the treatment of autoimmune and inflammatory diseases.